Resource Library

Conversations about weight loss often center on diets, medications, or the number on the scale. But for our very own Erica Terry, Director of Sales, Payer/PBM at Vida Health, the most important lesson was much simpler and far more powerful…

Over the past several years, obesity care has entered a new era of clinical sophistication…

Watch the on-demand webinar exploring how employers can move beyond access alone to build more effective GLP-1 strategies through integrated navigation, clinician oversight, and whole-person metabolic care.

See the outcomes of a large telecom company that executed responsible GLP-1 management and metabolic control through their partnership with Vida.

For decades, body mass index (BMI) has served as the shorthand for defining obesity and, by extension, metabolic health…

AI in telehealth must be governed by the principle of “do no harm” and must serve, not shape, care. AI improves care by reducing clinical workflow friction and streamlining data among other benefits however, when it comes to healthcare where do we have a responsibility to be sure humans are calling the shots?

See the outcomes of a coordinated solution that pairs Vida’s personalized care with Judi® -driven medication management promoting behavior change and appropriate use of GLP-1s.

GLP-1 medications have changed the conversation about metabolic care. It has also created a delicate balancing act between cost and accessibility for employers.

GLP-1 medications have changed the conversation about metabolic care. It has also created a delicate balancing act between cost and accessibility for employers, and the consultants who guide them.

Whether or not someone continues GLP-1 therapy is a clinical decision that should be made in partnership with their healthcare provider. But what are the strategic benefits, and what are the risks?

MASH isn’t a new problem, it’s a newly visible one. As obesity and diabetes continue to drive healthcare costs, metabolic liver disease is emerging as a critical missing piece in many employer strategies.

MASH is one of the fastest-growing and most overlooked drivers of metabolic risk and rising healthcare costs.